In Section C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment right until illness progression or the contributors are unable to tolerate the study drugs. Celastrol was discovered for a Myb inhibitor that suppressed C/EBPβ activity and repressed https://kirstenp887cnx0.wizzardsblog.com/profile